TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA”), a Phase 3 immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, announces the successful completion of the acquisition of Kineta, Inc. (OTCPK:KANT) (“Kineta”), the maker of the novel VISTA inhibiting mAb formerly known as KVA1213, now renamed as TBS-2025. “While TuHURA’s IFx-2.0 is being investigated for its potential to overcome primary resistance to checkpoint inhibitors in Merkel cell carcinoma, the acquisition of VISTA expands TuHURA’s pipeline with a Phase 2 ready drug candidate, TBS-2025, which TuHURA believes has the potential to overcome acquired resistance to cancer immunotherapy,” stated James Bianco, M.D., President and Chief Executive Officer of TuHURA.
Read the full article: TuHURA Biosciences Completes Acquisition of Kineta //
Source: https://www.prnewswire.com/news-releases/tuhura-biosciences-completes-acquisition-of-kineta-302494115.html